Business Wire10.20.16
Teleflex Incorporated, a global provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its Arrow Midline with Chlorag+ard Technology.
Arrow Midline with Chlorag+ard Technology is an antithrombogenic1 and antimicrobial2 peripheral venous catheter designed to minimize common midline catheter complications such as catheter intraluminal occlusion, thrombus accumulation and microbial colonization on the catheter surface for a minimum of 30 days.1,2,3 Additionally, the new midline is also designed for use with high-pressure injection for diagnostic studies. The Arrow Midline with Chlorag+ard Technology will enable caregivers to effectively and economically protect the catheter from potential costly complications.
“Clinicians are faced with a multitude of vascular access challenges. Development of new technology to ensure the patient receives the safest, most effective IV therapy possible should drive all medical device manufacturers. We at Teleflex continue to promote the message of ‘The Right Line for the Right Patient at the Right Time.’ and through this belief we continue to develop products that help clinicians to champion better care,” said Jay White, president and general manager of the Vascular Access Division of Teleflex. “The Arrow Midline with Chlorag+ard Technology continues to build upon this belief.”
References
1Data on file. AS compared to uncoated catheters, intravascular ovine model inoculated with Staph aureus. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
2In vitro data on file 2010. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.
3Occlusion—As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to human blood. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
Arrow Midline with Chlorag+ard Technology is an antithrombogenic1 and antimicrobial2 peripheral venous catheter designed to minimize common midline catheter complications such as catheter intraluminal occlusion, thrombus accumulation and microbial colonization on the catheter surface for a minimum of 30 days.1,2,3 Additionally, the new midline is also designed for use with high-pressure injection for diagnostic studies. The Arrow Midline with Chlorag+ard Technology will enable caregivers to effectively and economically protect the catheter from potential costly complications.
“Clinicians are faced with a multitude of vascular access challenges. Development of new technology to ensure the patient receives the safest, most effective IV therapy possible should drive all medical device manufacturers. We at Teleflex continue to promote the message of ‘The Right Line for the Right Patient at the Right Time.’ and through this belief we continue to develop products that help clinicians to champion better care,” said Jay White, president and general manager of the Vascular Access Division of Teleflex. “The Arrow Midline with Chlorag+ard Technology continues to build upon this belief.”
References
1Data on file. AS compared to uncoated catheters, intravascular ovine model inoculated with Staph aureus. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
2In vitro data on file 2010. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.
3Occlusion—As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to human blood. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.